Evoq Remedies Ltd
₹
- close price
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Other Income share of total income % ・Standalone data |
|
||||
| Number of related party entities with material transactions count ・Standalone data |
|||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Corporate Insolvency Resolution Process (CIRP)-Admission of application by Tribunal
- NCLT admitted Evoq Remedies into CIRP over Rs1.95 crore debt; moratorium and IRP appointed.
-
Corporate Insolvency Resolution Process (CIRP)-Admission of application by Tribunal
- Operational creditor filed Section 9 insolvency application against Evoq Remedies on 20 April 2026.
-
Integrated Filing (Finance) For The Half Year And Year Ended On 31St March, 2026
- Evoq Remedies posts FY26 loss of ₹25.10 lakh; auditor flags going-concern uncertainty, GST ₹655.03 lakh, SEBI probe.
-
Appointment Of M/S. Jay Pandya & Associates (FRN: S2024GJ963300), Company Secretaries, Ahmedabad, As Secretarial Auditor Of The Company For The Financial Year 2025-26.
- FY26 audited results approved on 30 May 2026; auditors issued qualified opinion citing going-concern risk and SEBI investigation.
-
Submission Of Audited Financial Results For The Half Year And Year Ended On 31St March, 2026 Along With Auditor'S Report.
- Board approved FY26 audited results; auditor issued qualified opinion citing going-concern risk, GST demand, SEBI probe.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
Business Overview:[1]
EVOQRL deals in the trading of the pharma
products and commission agent in pharma products, etc.